The United States of America, As Represented by the Secretary, Department of Health and Human Services

Glaxosmithkline Biologicals Sa

Zuzana Kossaczka

John B Robbins

Shousun Chen Szu

Rachel Schneerson

Joseph Shiloach

Ali Ibrahim Fattom

Sofiane Ennifar

Jawad Sarwar

Kimberly L Taylor

The disclosure pertains to conjugates of the capsular polysaccharide ofO139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against, in particularO139, and are useful to prevent, treat and/or reduce the severity of disease caused byinfection, such as cholera. The present disclosure also relates to diagnostic tests forinfection, and/or cholera caused byinfection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.

[object Object]

This invention relates to conjugates of the Vi polysaccharide ofwith the carrierrecombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of,bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againstand are useful to prevent and/or treat illnesses caused by

A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species ofor various types of

Method of protecting against staphylococcal infection

The invention pertains to conjugates of the capsular polysaccharide ofO139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against, in particularO139, and are useful to prevent, treat and/or reduce the severity of disease caused byinfection, such as cholera. The present invention also relates to diagnostic tests forinfection, and/or cholera caused byinfection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.

This invention relates to conjugates of the Vi polysaccharide of with the carrier recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt and are useful to prevent and/or treat illnesses caused by

Growing community of inventors

Bethesda, MD, United States of America

Zuzana Kossaczka